Evaluation of effect of Omega 3 on UTI (Cystitis and pyelonephritis) Symptoms

Determining the effect of omega-3 on the improvement of urinary infection symptoms

The present study is a clinical trial with a control group, with parallel groups, randomized (using block randomization), phase 3 on 100 patients.

In this double-blind randomization clinical trial, children with a definite diagnosis of urinary tract infection referred to Amirkabir Arak Hospital will be divided into two identical omega-3 groups by block randomization. In this study, the participants (by placebo pills) and the outcome assessor (by patient coding) will be blinded. In each group, drug treatment will be prescribed daily for 10 days. Finally, two groups will be evaluated in terms of study results.

Inclusion Criteria: children aged 4-18 years with urinary tract infection; Consent to participate in the study Exclusion Criteria: existence of underlying kidney and liver disease; Sensitivity to omega-3

Omega-3 group: In addition to receiving standard treatment (antibiotic suitable for symptoms, age and gender), children will receive mercury-free Omega-3 capsules produced by Zahrawi company for 10 days. Control group: In this group, children will receive only the standard treatment for 10 days.

Fever, Dysuria, frequency, abdominal pain, urinary incontinence

The participants will be assigned to two intervention and control groups based on the randomization sequence that will be generated in advance. This sequence is unpredictable and its arrangement is completely random. Block randomization method with 8 blocks will be used to allocate the samples. In this way, using the site www.sealedenvelope.com, blocks of 8 letters A and B are randomly generated based on the sample size. The order of placement of letters A and B in each block from the first block to the last block is considered as a randomization sequence. The production of these blocks and their random sequence is completely done by this site and the researcher does not know how they are sequenced.

This study is double blind. In this way, the intervention group will receive omega-3 along with routine treatment for urinary infection, while the placebo group will receive a similar placebo instead of omega-3. Therefore, the participants do not know the type of medicine received. On the other hand, prescribing the drugs is the responsibility of the supervisor, and the student, who evaluates the information, does not know about the grouping.

After conducting this study and analytical studies on it, only a part of the data such as information about the main outcome and patient demographic information will be published to the researchers who do the necessary correspondence with the person in charge of this study.

Access will be from 2024/09/20 to 2027/09/20 for 3 years.

University researchers

Academic researchers or university professors or students who intend to use the data of this study, after obtaining permission from the relevant people mentioned, can use the information of this study in the field of metallurgical studies or other relevant review studies. In addition, if requested, they can use the information of this study for the prerequisites of their future studies and the existence of questions and ambiguities. Using the information of this study is subject to mentioning the names and logos of the responsible persons in this study.

Academic researchers and university professors can request the use of data from Dr. Manijeh Kohbazi after contacting the relevant professor by message or email. Dr. Manijeh Kohbazi: Phone: 09181614351 Email: m_kahbazi77@yahoo.com Address: Arak, Amir Kabir Hospital, Hospital Education Vice-Chancellor

Letter writing should be done with professors and universities.